Veracyte Net Income Per Share from 2010 to 2024

VCYT Stock  USD 42.84  1.74  4.23%   
Veracyte Net Loss yearly trend continues to be comparatively stable with very little volatility. Net Loss will likely drop to -1.08 in 2024. From the period from 2010 to 2024, Veracyte Net Loss quarterly data regression had mean square error of  1.82 and mean deviation of  0.66. View All Fundamentals
 
Net Loss  
First Reported
2010-12-31
Previous Quarter
(1.02)
Current Value
(1.08)
Quarterly Volatility
1.37356907
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Veracyte financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Veracyte's main balance sheet or income statement drivers, such as Depreciation And Amortization of 28.5 M, Interest Expense of 14.2 K or Selling General Administrative of 165.5 M, as well as many indicators such as Price To Sales Ratio of 5.26, Dividend Yield of 0.0 or PTB Ratio of 1.82. Veracyte financial statements analysis is a perfect complement when working with Veracyte Valuation or Volatility modules.
  
Check out the analysis of Veracyte Correlation against competitors.
For more information on how to buy Veracyte Stock please use our How to Invest in Veracyte guide.

Latest Veracyte's Net Income Per Share Growth Pattern

Below is the plot of the Net Income Per Share of Veracyte over the last few years. It is Veracyte's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Veracyte's overall financial position and show how it may be relating to other accounts over time.
Net Income Per Share10 Years Trend
Slightly volatile
   Net Income Per Share   
       Timeline  

Veracyte Net Income Per Share Regression Statistics

Arithmetic Mean(1.30)
Coefficient Of Variation(105.45)
Mean Deviation0.66
Median(1.02)
Standard Deviation1.37
Sample Variance1.89
Range5.7938
R-Value0.33
Mean Square Error1.82
R-Squared0.11
Significance0.23
Slope0.10
Total Sum of Squares26.41

Veracyte Net Income Per Share History

2024 -1.08
2022 -0.51
2021 -1.11
2020 -0.67
2019 -0.36
2018 -0.62
2017 -0.91

About Veracyte Financial Statements

Veracyte shareholders use historical fundamental indicators, such as Net Income Per Share, to determine how well the company is positioned to perform in the future. Although Veracyte investors may analyze each financial statement separately, they are all interrelated. The changes in Veracyte's assets and liabilities, for example, are also reflected in the revenues and expenses on on Veracyte's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Net Loss(1.02)(1.08)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Veracyte Stock Analysis

When running Veracyte's price analysis, check to measure Veracyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Veracyte is operating at the current time. Most of Veracyte's value examination focuses on studying past and present price action to predict the probability of Veracyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Veracyte's price. Additionally, you may evaluate how the addition of Veracyte to your portfolios can decrease your overall portfolio volatility.